Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765497 | 0.87 | SLC10A2 (0.45) | SLC10A2MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL3777263 | 0.80 | SLC10A2 (0.56) | SLC10A2MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL11209986 | 0.79 | SMN1; SMN2 (0.45) | SLC10A2ALDH1A1SMN1; SMN2KDM4EGAA | |
| SCHEMBL16689300 | 0.78 | SMN1; SMN2 (0.44) | SLC10A2ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL27524113 | 0.77 | SMN1; SMN2 (0.49) | SLC10A2MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL14367995 | 0.77 | SMN1; SMN2 (0.42) | SLC10A2ALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL6766348 | 0.76 | SLC10A2 (0.46) | SLC10A2ALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL6767043 | 0.76 | SMN1; SMN2 (0.41) | SLC10A2ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL28008552 | 0.76 | SMN1; SMN2 (0.41) | SLC10A2ALDH1A1SMN1; SMN2KDM4ETUBB4A | |
| SCHEMBL16689327 | 0.76 | SMN1; SMN2 (0.41) | SLC10A2ALDH1A1SMN1; SMN2KDM4EPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750214-B2 | PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | COLLIS ALAN JOHN (US) | 2004-06-15 | — | — | US | disclosed |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-6642242-B2 | Antiproliferative agents to treat benign prostatic hyperplasia | PFIZER INC. | 2003-11-04 | — | — | US | disclosed |
| US-6103738-A | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0877734-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RES & DEV (IE) | 2000-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, ADRB3 | SLC10A2 1147/4885MEN1 266/4885KMT2A 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.